CTLT Insider Trading
CTLT | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at CTLT provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2022-08-27 03:23 | 2022-08-25 | Schmidt Kay A | Officer - SVP, Enterprise Functions | SELL | $103.04 | 1,321 | $136,116 | 17,388 | -7.1% |
| 2022-08-27 03:23 | 2022-08-25 | Riley Michael A. | Officer - Pres. Bio Product Delivery Div | SELL | $103.04 | 1,482 | $152,705 | 9,083 | -14.0% |
| 2022-08-27 03:21 | 2022-08-25 | Pravda Ricardo | Officer - SVP & Chief HR Officer | SELL | $103.04 | 1,747 | $180,011 | 20,008 | -8.0% |
| 2022-08-27 03:20 | 2022-08-25 | Maselli Alessandro | Director, Officer - President & CEO | SELL | $103.04 | 4,646 | $478,724 | 41,190 | -10.1% |
| 2022-08-27 03:20 | 2022-08-25 | Hunt Patricia | Officer - Pres. Consumer Health Div | SELL | $103.04 | 339 | $34,931 | 9,315 | -3.5% |
| 2022-08-27 03:19 | 2022-08-25 | Hopson Ricky | Officer - Pres. Clinical Dev Supply Div | SELL | $103.04 | 1,517 | $156,312 | 19,311 | -7.3% |
| 2022-08-27 03:19 | 2022-08-25 | Hawkeswood Thomas W | Officer - Pres. Pharma Prod Delivery Div | SELL | $103.04 | 671 | $69,140 | 6,294 | -9.6% |
| 2022-08-27 03:18 | 2022-08-25 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $103.04 | 1,840 | $189,594 | 25,627 | -6.7% |
| 2022-08-27 03:18 | 2022-08-25 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $103.04 | 1,670 | $172,077 | 20,243 | -7.6% |
| 2022-08-27 03:17 | 2022-08-25 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $103.04 | 1,645 | $169,501 | 86,769 | -1.9% |
| 2022-08-27 03:17 | 2022-08-25 | Gargiulo Mario | Officer - SVP Global Ops Biologics | SELL | $103.04 | 1,586 | $163,421 | 6,354 | -20.0% |
| 2022-08-27 03:16 | 2022-08-25 | Castellano Thomas P | Officer - SVP, Chief Financial Officer | SELL | $103.04 | 1,414 | $145,699 | 20,099 | -6.6% |
| 2022-08-27 03:15 | 2022-08-25 | Carletti Lorenzo | Officer - SVP Global Ops Ph & Cons Hlth | SELL | $103.04 | 1,033 | $106,440 | 4,985 | -17.2% |
| 2022-08-27 03:15 | 2022-08-25 | Boerman Manja | Officer - Pres. BioModalities Division | SELL | $103.04 | 3,296 | $339,620 | 16,640 | -16.5% |
| 2022-08-27 03:14 | 2022-08-25 | Arnold Jonathan | Officer - SVP & Chief Commercial Ofcr | SELL | $103.04 | 384 | $39,567 | 55,958 | -0.7% |
| 2022-08-27 03:16 | 2022-08-25 | Chiminski John R | Director, Officer - Executive Chair | SELL | $103.04 | 38,934 | $4,011,759 | 229,888 | -14.5% |
| 2022-08-27 03:16 | 2022-08-25 | Fasman Steven L | Officer - EVP & Chief Admin Officer | SELL | $103.04 | 4,811 | $495,725 | 61,853 | -7.2% |
| 2022-07-29 03:03 | 2022-07-26 | Schmidt Kay A | Officer - SVP, Enterprise Functions | SELL | $106.90 | 323 | $34,529 | 13,455 | -2.3% |
| 2022-07-29 03:01 | 2022-07-26 | Pravda Ricardo | Officer - SVP & Chief HR Officer | SELL | $106.90 | 427 | $45,646 | 15,337 | -2.7% |
| 2022-07-29 03:00 | 2022-07-26 | Maselli Alessandro | Director, Officer - President & CEO | SELL | $106.90 | 816 | $87,230 | 25,083 | -3.2% |
| 2022-07-29 02:59 | 2022-07-26 | Hopson Ricky | Officer - Pres, Clinical Dev & Supply | SELL | $107.40 | 903 | $96,986 | 17,095 | -5.0% |
| 2022-07-29 02:58 | 2022-07-26 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $107.26 | 844 | $90,527 | 22,350 | -3.6% |
| 2022-07-29 02:46 | 2022-07-26 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $107.27 | 797 | $85,498 | 17,023 | -4.5% |
| 2022-07-29 02:45 | 2022-07-26 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $106.90 | 403 | $43,081 | 79,784 | -0.5% |
| 2022-07-29 02:43 | 2022-07-26 | Gargiulo Mario | Officer - SVP Global Ops Biologics | SELL | $106.90 | 969 | $103,586 | 3,671 | -20.9% |
| 2022-07-29 02:39 | 2022-07-26 | Castellano Thomas P | Officer - SVP, Chief Financial Officer | SELL | $106.90 | 347 | $37,094 | 15,051 | -2.3% |
| 2022-07-29 02:39 | 2022-07-26 | Carletti Lorenzo | Officer - SVP Global Ops Ph & Cons Hlth | SELL | $106.90 | 631 | $67,454 | 2,949 | -17.6% |
| 2022-07-29 02:35 | 2022-07-26 | Arnold Jonathan | Officer - SVP & Chief Commercial Ofcr | SELL | $106.90 | 94 | $10,049 | 48,698 | -0.2% |
| 2022-07-29 02:41 | 2022-07-26 | Chiminski John R | Director, Officer - Executive Chair | SELL | $106.90 | 9,691 | $1,035,968 | 132,382 | -6.8% |
| 2022-07-29 02:42 | 2022-07-26 | Fasman Steven L | Officer - EVP & Chief Admin Officer | SELL | $106.90 | 2,546 | $272,167 | 53,721 | -4.5% |
| 2022-06-13 23:58 | 2022-06-10 | Gargiulo Mario | Officer - SVP Global Ops Large Molecule | SELL | $106.59 | 118 | $12,578 | 4,640 | -2.5% |
| 2022-06-13 23:57 | 2022-06-10 | Fasman Steven L | Officer - SVP & General Counsel | SELL | $107.07 | 5,000 | $535,353 | 56,178 | -8.2% |
| 2022-02-09 05:31 | 2022-02-06 | Zippelius Peter | Director | SELL | $102.65 | 487,092 | $49,999,994 | 4,330,462 | -10.1% |
| 2022-02-01 23:38 | 2022-01-31 | Hopson Ricky | Officer - VP, Chief Accounting Officer | SELL | $103.39 | 2,325 | $240,382 | 17,073 | -12.0% |
| 2022-01-25 00:42 | 2022-01-21 | Whitlow Ricci S | Officer - President, CSS | SELL | $102.37 | 184 | $18,836 | 2,923 | -5.9% |
| 2022-01-12 02:54 | 2022-01-10 | Flynn Karen | Officer - Chief Commercial Officer | SELL | $116.64 | 2,472 | $288,334 | 33,223 | -6.9% |
| 2021-12-02 04:35 | 2021-11-30 | Zippelius Peter | Director | SELL | $129.30 | 3,000,000 | $387,900,000 | 4,822,946 | -38.3% |
| 2021-11-24 20:40 | 2021-11-23 | LUCIER GREGORY T | Director | SELL | $127.35 | 5,068 | $645,407 | 0 | -100.0% |
| 2021-11-03 22:35 | 2021-11-01 | Arnold Jonathan | Officer - Pres. Oral & Specialty Deliv. | OPT+S | $140.02 | 10,672 | $1,494,293 | 41,971 | 0.0% |
| 2021-10-22 02:16 | 2021-10-20 | Castellano Thomas P | Officer - SVP, Chief Financial Officer | SELL | $134.00 | 2,307 | $309,138 | 15,398 | -13.0% |
| 2021-10-18 21:33 | 2021-10-14 | Arnold Jonathan | Officer - Pres. Oral & Specialty Deliv. | SELL | $129.41 | 1,661 | $214,950 | 45,084 | -3.6% |
| 2021-10-07 00:37 | 2021-10-04 | Schmidt Kay A | Officer - SVP, Technical Operations | SELL | $131.25 | 2,191 | $287,569 | 13,778 | -13.7% |
| 2021-10-07 00:37 | 2021-10-04 | Fasman Steven L | Officer - SVP & General Counsel | OPT+S | $129.05 | 34,714 | $4,479,974 | 57,133 | 0.0% |
| 2021-10-06 01:51 | 2021-10-01 | Pravda Ricardo | Officer - SVP & Chief HR Officer | OPT+S | $132.68 | 4,906 | $650,928 | 11,747 | 0.0% |
| 2021-10-06 01:51 | 2021-10-01 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $131.66 | 2,055 | $270,557 | 12,502 | -14.1% |
| 2021-10-06 01:51 | 2021-10-01 | Chiminski John R | Director, Officer - Chair & CEO | OPT+S | $130.90 | 152,637 | $19,979,603 | 142,073 | 0.0% |
| 2021-08-31 04:43 | 2021-08-27 | Castellano Thomas P | Officer - SVP, Chief Financial Officer | SELL | $131.13 | 2,093 | $274,458 | 17,705 | -10.6% |
| 2021-08-31 04:43 | 2021-08-27 | Schmidt Kay A | Officer - SVP, Technical Operations | SELL | $131.13 | 825 | $108,183 | 15,969 | -4.9% |
| 2021-08-31 04:42 | 2021-08-27 | Hopson Ricky | Officer - VP, Chief Accounting Officer | SELL | $131.13 | 1,471 | $192,894 | 19,398 | -7.0% |
| 2021-08-31 04:42 | 2021-08-27 | Pravda Ricardo | Officer - SVP & Chief HR Officer | SELL | $131.13 | 692 | $90,742 | 12,835 | -5.1% |
How to Interpret $CTLT Trades
Not every insider transaction in CTLT is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CTLT shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CTLT
Insider activity data for CTLT is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CTLT, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.